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Background-—No data are available on the long-term performance of ultrathin strut biodegradable polymer sirolimus-eluting stents
(BP-SES). We reported 2-year clinical outcomes of the BIOSCIENCE (Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent
Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularisation) trial, which compared BP-SES with
durable-polymer everolimus-eluting stents (DP-EES) in patients undergoing percutaneous coronary intervention.
Methods and Results-—A total of 2119 patients with minimal exclusion criteria were assigned to treatment with BP-SES
(n=1063) or DP-EES (n=1056). Follow-up at 2 years was available for 2048 patients (97%). The primary end point was target-
lesion failure, a composite of cardiac death, target-vessel myocardial infarction, or clinically indicated target-lesion
revascularization. At 2 years, target-lesion failure occurred in 107 patients (10.5%) in the BP-SES arm and 107 patients
(10.4%) in the DP-EES arm (risk ratio [RR] 1.00, 95% CI 0.77–1.31, P=0.979). There were no signiﬁcant differences between BP-
SES and DP-EES with respect to cardiac death (RR 1.01, 95% CI 0.62–1.63, P=0.984), target-vessel myocardial infarction (RR
0.91, 95% CI 0.60–1.39, P=0.669), target-lesion revascularization (RR 1.17, 95% CI 0.81–1.71, P=0.403), and deﬁnite stent
thrombosis (RR 1.38, 95% CI 0.56–3.44, P=0.485). There were 2 cases (0.2%) of deﬁnite very late stent thrombosis in the BP-
SES arm and 4 cases (0.4%) in the DP-EES arm (P=0.423). In the prespeciﬁed subgroup of patients with ST-segment elevation
myocardial infarction, BP-SES was associated with a lower risk of target-lesion failure compared with DP-EES (RR 0.48, 95% CI
0.23–0.99, P=0.043, Pinteraction=0.026).
Conclusions-—Comparable safety and efﬁcacy proﬁles of BP-SES and DP-EES were maintained throughout 2 years of follow-up.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01443104. ( J Am Heart Assoc. 2016;5:
e003255 doi: 10.1161/JAHA.116.003255)
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N ewer generation drug-eluting stents (DESs) representthe standard of care in patients undergoing percuta-
neous coronary intervention (PCI) and are recommended for
all patient and lesion subsets.1,2 The crucial shortcoming of
early generation DESs was a delayed healing response of the
stented coronary artery, resulting in an increase in late
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thrombotic events.3 Newer generation DESs were developed
featuring biocompatible or biodegradable polymers that
release -limus analogues at lower dosages.4,5 These reﬁne-
ments resulted not only in a remarkable reduction in the risk
of stent thrombosis (ST) compared with early generation
DESs but also improved efﬁcacy (lower risk of repeat
revascularization) and safety (lower risk of death and
myocardial infarction [MI]).6
The biodegradable-polymer sirolimus-eluting stent (BP-SES;
Orsiro; Biotronik AG) represents a further iteration of DES
technology by combining a biodegradable polymer with an
ultrathin-strut cobalt–chromium platform (60 lm for stent
diameters up to 3.0 mm, 80 lm for stent diameters >3 mm).
In the BIOSCIENCE (Ultrathin Strut Biodegradable Polymer
Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-
Eluting Stent for Percutaneous Coronary Revascularisation)
trial, the BP-SES was noninferior to the durable-polymer
everolimus-eluting stent (DP-EES) with respect to the primary
composite safety and efﬁcacy end point of target-lesion failure
at 12 months.7 Nevertheless, long-term comparative data on
biodegradable- anddurable-polymer newer generationDESs are
sparse and limited mainly to thick-strut biodegradable-polymer
DESs (BP-DESs). Consequently, the purpose of the present
study was to report the long-term clinical outcomes of patients
included in the BIOSCIENCE trial over 2 years of follow-up.
Methods
Study Design and Patient Population
BIOSCIENCE was an investigator-initiated, single-blind, multi-
center, randomized noninferiority trial with minimal exclusion
criteria (ClinicalTrials.gov,NCT01443104).Thestudydesignand
the principal features of the study devices have been detailed
previously.8 Study enrollmentwas performedbetween February
2012 and May 2013 at 9 centers in Switzerland. Patients were
randomly assigned to treatment with BP-SES or DP-EES (Xience
Prime or Xpedition stent; Abbott Vascular). There were no
restrictions on the number of treated lesions, the number of
vessels, or the lesion length. Main exclusion criteria were
intolerance to aspirin, clopidogrel, or DES components and
planned surgery within 6 months at the time of index PCI. The
study complied with the Declaration of Helsinki and was
approved by the institutional ethics committees of all partici-
pating sites. All patients provided written informed consent for
participation in the trial.
Randomization and Procedures
After diagnostic angiography, patients were randomly allo-
cated at a 1:1 ratio to treatment with BP-SES or DP-EES using
a centralized, Web-based randomization system. Randomiza-
tion was stratiﬁed according to center and to presence or
absence of ST-segment elevation MI (STEMI). Study
participants and outcome assessors were masked to the
allocated DES, whereas treating physicians were not.
PCI was performed according to current guidelines. Lesion
predilation, direct stenting, and postdilatation were done at the
operator’s discretion. During the procedure, patientswere given
unfractionated heparin at a dose of at least 5000 IU or 70–
100 IU/kg. The use of glycoprotein IIb/IIIa inhibitors or
bivalirudin during PCI was left to the discretion of the operator.
Antiplatelet treatment was initiated before or at the time of PCI
and consisted of acetylsalicylic acid (>250 mg) in combination
with a loading dose of clopidogrel 600 mg, prasugrel 60 mg, or
ticagrelor 180 mg. Dual antiplatelet therapywas recommended
for a duration of 12 months after stent implantation and
consisted of acetylsalicylic acid 100 mg daily and a P2Y12
inhibitor (75 mg clopidogrel once per day, 10 mg prasugrel
once per day, or 90 mg ticagrelor twice per day), followed by
acetylsalicylic monotherapy indeﬁnitely.
Clinical End Points
The primary end point of target-lesion failure (TLF) was a
composite of cardiac death, target-vessel MI, and clinically
indicated target-lesion revascularization at 12 months. The
deﬁnition of cardiac death included any death due to immediate
cardiac cause, deaths related to the procedure, unwitnessed
death,anddeath fromunknowncause.MIwasdifferentiated into
Q-wave and non–Q-wave MI. Spontaneous MI was documented
incaseofa typical riseand fall ofcreatininekinase-MBfractionor
troponin in the presence of ≥1 of the following conditions:
ischemic symptoms, new pathological Q waves, ischemic
electrocardiographic changes, or pathological evidenceof acute
MI. Target vessel–related MI was considered in cases in which
the MI was related to the target vessel or the MI was not clearly
related to another vessel. Target-lesion revascularization was
deﬁned as any repeated percutaneous or surgical intervention
due toastenosisorocclusionwithin thestentorwithin the5-mm
borders proximal or distal to the stent. ST was categorized
according to the deﬁnitions provided by the Academic Research
Consortium.9 A revascularizationwas considered to be clinically
indicated if the stenosis of the treated lesionwas at least 50% of
the lumen diameter in the presence of signs or symptoms of
ischemia or if the diameter stenosis was at least 70% of the
lumen diameter, regardless of the presence or absence of
ischemic signs and symptoms. Target-vessel failure was a
composite of cardiac death, MI that could not be clearly
attributed to a vessel other than the target vessel, and target-
vessel revascularization. Secondary end points were clinically
indicated and not clinically indicated target-lesion revascular-
ization; clinically indicated and not clinically indicated target-
vessel revascularization; target-vessel failure; cardiac death; all
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death; MI; deﬁnite ST; and deﬁnite or probable ST. All data were
stored in a central database (Cardiobase; Clinical Trials Unit and
Department of Cardiology at Bern University Hospital and 2mT
Software GmbH). Follow-up visits were performed at 30 days,
12 months, and 24 months. Patients were questioned about
the occurrence of angina, any adverse events, hospital admis-
sions, and cardiovascular medication intake. Electrocardio-
graphs were systematically collected at baseline, after the
procedure, at 12-month follow-up, and in case of recurrent
signs or symptoms of ischemia. All serious adverse events were
blinded and submitted to the Clinical Trials Unit of theUniversity
of Bern. Any death, reinfarction, revascularization, ST, cere-
brovascular accident, and bleeding event was independently
adjudicated by a clinical events committee blinded to treatment
allocation.
Statistical Analysis
The trial was powered for noninferiority of BP-SES compared
with DP-EES with respect to the primary clinical end point,
TLF, at 12 months. With a noninferiority margin of 3.5%, the
enrollment of 2060 patients was calculated to provide >80%
power to detect noninferiority at a 1-sided type 1 error of
0.05. For this prespeciﬁed analysis, we calculated the 2-sided
95% CI and 2-sided P-value for superiority for all end points.
Speciﬁcally, we used the Mantel–Cox method to calculate risk
ratio (RR) with 95% CI from the log-rank test. We used time to
ﬁrst event for each type of outcome throughout and reported
Kaplan–Meier estimates of event rates. A landmark analysis
was performed by using the 1-year landmark. For each type of
event, patients were censored at the time of the ﬁrst event:
A patient who experienced an event contributing to the
primary composite end point during 365 days, for example,
was censored at the time of the event and excluded from the
analysis after the landmark point. P values for characteristics
recorded at the patient level are from unpaired t tests, v²
tests, or Fisher exact tests, except when speciﬁed. P values
for characteristics that were recorded at the lesion level are
from general or generalized linear mixed models to account
for the nonindependence of lesions in the same patient. We
prespeciﬁed stratiﬁed analyses of the primary end point for
the following subgroups: diabetes, acute coronary syndrome
status, STEMI, sex, age ≥65 years, obesity, and renal failure.
To identify interactions between groups and for each of these
characteristics on the effect size, we approximated Mantel–
Haenszel v² tests for effect modiﬁcation. All patients who
were randomly assigned and provided written informed
consent were included in the analyses of end points according
to the intention-to-treat principle. Analyses were done by a
statistician at the Clinical Trials Unit of the University of Bern
and carried out with Stata statistical software release 13
(StataCorp LP).
Results
A total of 2129 patients with coronary artery disease were
randomized to treatment with BP-SES (1066 patients) or DP-
EES (1063 patients). After exclusion of 10 patients who did
not conﬁrm their initial consent, 1063 patients with 1594
lesions who were randomly assigned to BP-SES and 1056
patients with 1545 lesions who were randomly assigned to
DP-EES remained for the ﬁnal analysis. Overall, 39 patients
(3.7%) allocated to BP-SES and 32 (3%) allocated to DP-EES
were lost to follow-up or withdrew consent before reaching
24 months, without between-group differences (Figure 1).
Baseline patient characteristics have been shown previously.7
In brief, parameters were well balanced between the 2
treatment arms with respect to age, sex, cardiovascular risk
factors, and previous revascularization procedures. More than
50% of the patients presented with an acute coronary
syndrome. There was a signiﬁcant difference with regard to
stent length, which was signiﬁcantly longer in the DP-EES arm
compared with the BP-SES arm (27.516.8 mm versus
25.915.4 mm; P=0.01).
Table shows clinical outcomes at 2 years. At 2 years, we
established noninferiority of BP-SES for the primary end point,
with an absolute risk difference of 0.07% and the upper limit
of the 1-sided 95% CI of 2.50% (P=0.0032 in 1-sided
noninferiority analysis). Subsequent superiority testing for
the primary end point did not yield signiﬁcant differences
between BP-SES and DP-EES (10.5% versus 10.4%, respec-
tively; RR 1.00, 95% CI 0.77–1.31, P=0.979) (Figure 2A).
The rates of the individual components of the primary end
point, including cardiac death, target-vessel MI, and clinically
indicated target-lesion revascularization, were comparable for
the 2 treatment arms and are illustrated in Figure 2B through
2D. Similarly, no signiﬁcant differences were noted for any of
the secondary end points (Table). Of note, there was a higher
rate of all-cause death in patients treated with BP-SES
compared with DP-EES (6.0% versus 4.0%; P=0.047) because
of an excess of noncardiovascular deaths in the BP-SES arm
(Table S1). In a landmark analysis for the primary end point
and its components with the landmark set at 1 year, we found
no difference in late events between 1 and 2 years (Figure 3).
The landmark analysis for all study end points is presented in
Table S2. The rate of deﬁnite ST was similar in the 2 treatment
arms (1.1% versus 0.8%, P=0.485) (Table). Very late deﬁnite
ST occurred in 2 (0.2%) versus 4 (0.4%) patients allocated to
BP-SES and DP-EES, respectively (Table S2). At 2 years of
follow-up, 15.2% of the patients allocated to BP-SES and
14.5% of patients allocated to DP-EES were still on dual
antiplatelet therapy (P=0.66).
Findings for the primary end point were consistent across
major subgroups such as age, sex, diabetes, acute coronary
syndrome, body mass index, and renal failure (Figure 4). In
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the prespeciﬁed subgroup of patients presenting with STEMI,
patients treated with BP-SES were documented to have a
lower risk of TLF than patients allocated to DP-EES (RR 0.48,
95% CI, 0.23–0.99, P=0.043), with a signiﬁcant interaction
between the type of stent and the presence or absence of
STEMI (P=0.026).
Discussion
To the best of our knowledge, this study is the ﬁrst report of
2-year clinical outcomes of newer generation DESs combining
a biodegradable polymer with an ultrathin cobalt–chromium
platform compared with DP-EES from a randomized controlled
trial. The 2-year results of the BIOSCIENCE trial corroborate
the primary end point results at 1 year7 and demonstrate
comparable rates of clinical outcomes throughout 2 years of
follow-up in a patient population with minimal exclusion
criteria treated with BP-SES or DP-EES.
Newer generation DESs were developed with the aim of
overcoming the limitations of early generation DESs that
were associated with a higher risk of late thrombotic events
compared with bare-metal stents. The increased risk of very
late ST resulted from incomplete strut endothelialization
related to a persistent inﬂammatory reaction caused by a
hypersensitivity reaction to the polymer. Current evidence
suggests better safety and efﬁcacy proﬁles for both
biodegradable- and durable-polymer newer-generation DESs
compared with early generation DESs.2,4 The 5-year follow-up
of the LEADERS (Limus Eluted From A Durable Versus
ERodable Stent Coating) trial showed a signiﬁcant reduction
of the risk of very late ST and associated clinical end points
in patients treated with biodegradable-polymer biolimus-
eluting stents (BP-BES) compared with patients treated with
early generation sirolimus-eluting stents.10 At this time, it is
controversial whether the safety proﬁle of the BP-BES, which
represents the most studied BP-DES, is equivalent to the
Figure 1. Patient ﬂow according to the CONSORT statement. BMS indicates bare-metal stent; BP-SES, biodegradable-polymer sirolimus-
eluting stent; CABG, coronary artery bypass grafting; DES, drug-eluting stent; DP-EES, durable-polymer everolimus-eluting stent; PCI,
percutaneous coronary intervention.
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Table. Clinical Outcomes
BP-SES DP-EES Risk Difference, BP-SES vs DP-EES, % RR, BP-SES vs DP-EES
P Valuen=1063 n=1056 (95% CI) (95% CI)
All-cause death 62 (6.0) 42 (4.0) 1.86 (0.02 to 3.69) 1.48 (1.00–2.20) 0.047
Cardiac death 33 (3.2) 33 (3.2) 0.02 (1.50 to 1.46) 1.01 (0.62–1.63) 0.984
Myocardial infarction 62 (6.1) 73 (7.2) 1.08 (3.16 to 1.00) 0.85 (0.60–1.19) 0.344
Q-wave 12 (1.2) 11 (1.1) 0.09 (0.80 to 0.97) 1.09 (0.48–2.48) 0.831
Non Q-wave 51 (5.0) 63 (6.2) 1.17 (3.09 to 0.75) 0.81 (0.56–1.17) 0.258
Target-vessel MI 42 (4.1) 46 (4.5) 0.40 (2.10 to 1.29) 0.91 (0.60–1.39) 0.669
Q-wave 12 (1.2) 8 (0.8) 0.37 (0.45 to 1.19) 1.50 (0.61–3.68) 0.369
Non–Q-wave 30 (2.9) 38 (3.7) 0.78 (2.28 to 0.72) 0.79 (0.49–1.27) 0.327
Cardiac death or MI 92 (8.9) 101 (9.8) 0.91 (3.36 to 1.54) 0.91 (0.69–1.21) 0.518
Repeat revascularisation 126 (12.6) 113 (11.2) 1.15 (1.54 to 3.85) 1.14 (0.88–1.47) 0.320
Percutaneous repeat revascularization 123 (12.3) 111 (11.0) 1.06 (1.61 to 3.73) 1.13 (0.87–1.46) 0.348
Surgical repeat revascularization 5 (0.5) 7 (0.7) 0.19 (0.83 to 0.45) 0.72 (0.23–2.26) 0.566
TLR 64 (6.4) 58 (5.8) 0.53 (1.45 to 2.51) 1.12 (0.78–1.60) 0.539
Clinically indicated TLR 59 (6.0) 51 (5.1) 0.72 (1.17 to 2.61) 1.17 (0.81–1.71) 0.403
Percutaneous TLR 56 (5.7) 49 (4.9) 0.63 (1.22 to 2.48) 1.16 (0.79–1.70) 0.451
Surgical TLR 4 (0.4) 4 (0.4) 0.00 (0.52 to 0.52) 1.00 (0.25–4.02) 0.995
TVR 81 (8.1) 75 (7.5) 0.52 (1.71 to 2.74) 1.10 (0.80–1.50) 0.568
Clinically indicated TVR 77 (7.7) 68 (6.8) 0.80 (1.35 to 2.95) 1.15 (0.83–1.59) 0.399
Percutaneous TVR 74 (7.4) 67 (6.7) 0.62 (1.51 to 2.74) 1.12 (0.81–1.56) 0.496
Surgical TVR 4 (0.4) 4 (0.4) 0.00 (0.52 to 0.52) 1.00 (0.25–4.02) 0.995
Cerebrovascular event 19 (1.9) 20 (2.0) 0.11 (1.25 to 1.04) 0.95 (0.51–1.79) 0.883
Transient ischemic attack 5 (0.5) 4 (0.4) 0.09 (0.46 to 0.65) 1.26 (0.34–4.68) 0.733
Stroke* 15 (1.5) 17 (1.7) 0.20 (1.24 to 0.84) 0.89 (0.44–1.77) 0.731
Ischemic stroke 13 (1.3) 17 (1.7) 0.39 (1.39 to 0.62) 0.77 (0.37–1.58) 0.469
Target-lesion failure† 107 (10.5) 107 (10.4) 0.07 (2.63 to 2.50) 1.00 (0.77–1.31) 0.979
Target-vessel failure‡ 124 (12.2) 127 (12.3) 0.36 (3.11 to 2.39) 0.98 (0.77–1.26) 0.882
Death, MI, or repeat revascularization§ 197 (19.1) 176 (17.0) 1.87 (1.38 to 5.11) 1.13 (0.92–1.39) 0.237
Definite stent thrombosis 11 (1.1) 8 (0.8) 0.28 (0.53 to 1.08) 1.38 (0.56–3.44) 0.485
Definite or probable stent thrombosis 40 (3.9) 50 (4.9) 0.97 (2.69 to 0.75) 0.80 (0.53–1.21) 0.287
Bleeding event
BARC type 3 to 5 36 (3.5) 36 (3.5) 0.02 (1.57 to 1.52) 1.00 (0.63–1.59) 0.999
BARC type 2 25 (2.5) 31 (3.0) 0.58 (1.95 to 0.78) 0.80 (0.47–1.36) 0.417
BARC type 3a 17 (1.7) 10 (1.0) 0.65 (0.30 to 1.61) 1.71 (0.78–3.72) 0.175
BARC type 3b 12 (1.2) 22 (2.1) 0.95 (2.02 to 0.12) 0.54 (0.27–1.10) 0.085
BARC type 3c 4 (0.4) 2 (0.2) 0.19 (0.27 to 0.64) 2.01 (0.37–11.08) 0.411
BARC type 4 1 (0.1) 1 (0.1) 0.00 (0.26 to 0.26) 1.00 (0.06–15.88) 0.998
BARC type 5a 1 (0.1) 1 (0.1) 0.00 (0.26 to 0.26) 1.01 (0.06–15.95) 0.996
BARC type 5b 3 (0.3) 1 (0.1) 0.19 (0.18 to 0.56) 3.01 (0.31–29.12) 0.318
Number of ﬁrst events and cumulative incidence percentage are reported. RR (95% CI) is estimated using the Mantel–Cox method with 2-sided P values from log-rank test. Continuity
corrected RR with Fisher exact test for zero outcomes. BARC indicates Bleeding Academic Research Consortium; BP-SES, biodegradable-polymer sirolimus-eluting stent; DP-EES, durable-
polymer everolimus-eluting stent; MI, myocardial infarction; RR, risk ratio; TLR, target-lesion revascularization; TVR, target-vessel revascularization.
*Includes ischemic stroke, intracerebral hemorrhagic stroke, and unclear etiology cerebrovascular event.
†Primary end point, deﬁned as the composite of cardiac death, target-vessel Q-wave or non–Q wave MI, and clinically indicated TLR.
‡Deﬁned as the composite of cardiac death, any Q-wave or non–Q wave MI, and any TVR.
§Patient-oriented composite end point.
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safety proﬁle of the DP-EES. In direct randomized compar-
isons, the BP-BES had a safety proﬁle equivalent to that of
the DP-EES, with a similar risk of MI and ST11–14; however,
individual head-to-head comparisons were not powered to
assess differences in MI and ST, and data from network
meta-analyses suggest a lower safety proﬁle of the BP-BES.
In a network meta-analysis including 63 242 patients,
Navarese and colleagues reported a signiﬁcant increase in
the odds of MI with the BP-BES compared with the DP-EES.15
Another network meta-analysis documented a higher risk of
ST among patients treated with the BP-BES compared with
the DP-EES; the difference was driven by an increased risk of
early ST (within the ﬁrst 30 days).16 In this context, it is
noteworthy that the BP-BES is based on a relatively thick-
strut stainless steel platform with a strut thickness of
120 lm and uses an abluminally distributed polymer of 10-
lm thickness.17 In comparison, both BP-SES and DP-EES use
thinner strut (60 or 80 lm and 81 lm, respectively) and
polymer (7 and 8 lm, respectively) coating thicknesses.2 It
has been reported that strut thickness and geometry greatly
modulate stent thrombogenicity, particularly during the early
phase after stent implantation.18 These observations may in
part explain the results of the SORT OUT (Scandinavian
Organization for Randomized Trials with Clinical Outcome) VII
trial, which compared the thin-strut BP-SES with the thick-
strut BP-BES among 2525 patients undergoing PCI.19 At 12
months, the study found a signiﬁcantly lower rate of deﬁnite
ST with the BP-SES (0.4% versus 1.2%), with an excess of ST
cases in the BP-BES arm during the early period following
PCI.
In a large network meta-analysis, Bangalore and colleagues
reported a higher risk of target-vessel revascularization and
late mortality with BP-DES compared with new-generation DP-
DES.20 It is noteworthy that 17 different BP-DES devices were
included under the same node,20 bringing into question
whether the results of various BP-DESs should be interpreted
as a single category rather than individually. In view of the
recent evidence, it seems appropriate to disentangle at least
Figure 2. Kaplan-Meier curves for the primary end point (panel A) and its compenents (panels B-D) at 2-year follow-up. The blue line shows the
BP-SES, and the red line shows the DP-EES. BP-SES indicates biodegradable-polymer sirolimus-eluting stent; DP-EES, durable-polymer
everolimus-eluting stent; RR, risk ratio; TLR, target-lesion revascularization.
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thin-strut from thick-strut BP-DESs for the interpretation of
clinical data.
The BIOSCIENCE trial showed excellent safety and efﬁcacy
proﬁles for both the BP-SES and the DP-EES, without any
difference in late adverse events between 1 and 2 years. The
rate of very late ST was low for both BP-SES and DP-EES (0.2%
and 0.4%), and target-vessel MI occurred in 1.3% of patients in
both treatments arms beyond 1 year. Moreover, the sustained
similar efﬁcacy in terms of target-lesion revascularization for
BP-SES and DP-EES at 2 years (6.0% versus 5.1%) is in line
with the excellent late lumen loss found in the BIOFLOW
(Biotronik-Safety and Clinical Performance of the Drug Eluting
Orsiro Stent in the Treatment of Subjects With Single De Novo
Coronary Artery Lesions) II trial at 9-month angiographic
follow-up (0.100.32 versus 0.110.29 mm for BP-SES
versus DP-EES).21
We found a higher risk of all-cause death in the BP-SES arm
compared with the DP-EES arm. The difference was due to an
excess in noncardiovascular death in the BP-SES arm and may
result from chance.
Recently, 2 randomized trials powered for a clinical primary
end point reported the results of thin-strut BP-DES versus DP-
EES. The CENTURY (Clinical Evaluation of New TerUmo dRug-
eluting coronary stent) II trial allocated 1123 PCI patients to
receive the Ultimaster BP-SES (Terumo Corporation) or DP-
EES.22 At 9 months, noninferiority with regard to the primary
end point of TLF was established, without any signiﬁcant
difference in secondary end points between the 2 treatment
arms.22 Similarly, the EVOLVE (A Prospective Randomized
Multicenter Single-blind Noninferiority Trial to Assess the
Safety and Performance of the Evolution Everolimus-Eluting
Monorail Coronary Stent System for the Treatment of a De
novo Atherosclerotic Lesion) II trial compared a thin-strut BP-
EES with DP-EES in a relatively lower risk PCI cohort of 1684
patients.23 At 12 months, the BP-EES was noninferior to DP-
EES with respect to the primary end point of TLF23; however,
longer follow-up data beyond the ﬁrst year are still forthcom-
ing for these studies.
A potential beneﬁt of BP-SES compared with DP-EES in the
subgroup of patients presenting with STEMI observed at
Figure 3. Kaplan–Meier curves for the landmark analyses of the primary end point and its components. The blue line shows the BP-SES, and
the red line shows the DP-EES. TLR indicates target-lesion revascularization; TV, target vessel.
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1 year was maintained throughout 2 years of follow-up;
however, the effect at 2 years (RR 0.48, 95% CI 0.23–0.99)
was attenuated compared with the effect at 1 year (RR 0.38,
95% CI 0.16–0.91).7,24 The observation is relevant because of
previous concerns related to DP-SES25,26 and is consistent
with data from thick-strut BP-DES.27,28 In an individual data–
pooled analysis of 497 STEMI patients from 3 randomized
controlled trials comparing thick-strut stainless steel BP-DESs
with early generation SESs, the difference in favor of BP-DES
emerged in the ﬁrst year after PCI and remained stable
thereafter.28 Biodegradable polymers may enhance arterial
healing in the inﬂammatory milieu of STEMI and reduce the
number of uncovered struts; however, the results in STEMI
patients were at variance with patients with non–ST-segment
elevation acute coronary syndrome, in whom the risk of TLF
trended higher with BP-SES compared with DP-EES (RR 1.52,
95% CI 0.94–2.48, P=0.086). Along with this limitation, the
relatively modest sample size of STEMI patients (n=407)
represents a further reason to use caution in interpreting the
ﬁndings observed in this subgroup that may well be related to
chance.
Our results should be interpreted in light of the following
limitations. First, we are unable to report the number of
eligible patients not included in the trial during the study
period because the protocol did not regulate the use of a
screening log. Second, the study was powered for the
primary composite end point of TLF; therefore, our analysis
remains underpowered to detect differences in the individual
components of the primary end point or in rare events, such
as very late ST. Third, the biodegradable polymer of the BP-
SES degrades over a period of 12 to 24 months. Conse-
quently, potential differences between BP-SES and DP-EES
may unfold only during very long-term follow-up. Fourth,
some adverse events may be related to previously implanted
stents und unrelated to the study devices; however, all
potential events were adjudicated by a blinded clinical
events committee and classiﬁed according to their relation
to the assigned study stent. Finally, although the greater
beneﬁt with BP-SES in the subgroup of patients with STEMI
persisted after 2 years of follow-up, this ﬁnding should be
considered hypothesis generating and warrants further
study.
In conclusion, the 2-year follow-up of the BIOSCIENCE trial
conﬁrms equivalent safety and efﬁcacy proﬁles of BP-SES and
DP-EES. The rate of adverse events beyond 1 year was low
and comparable for both treatment arms, with a low rate of
very late ST. Whether differences in clinical outcomes emerge
beyond 2 years needs to be further investigated.
Figure 4. Stratiﬁed analysis of target-lesion failure at 2 years across prespeciﬁed subgroups. Number of ﬁrst events and percentages are
reported. Rate ratios with 95% CIs are estimated using the Mantel–Cox method with 2-sided P values from log-rank test. Renal failure indicates a
creatinine-estimated glomerular ﬁltration rate of <60 mL/min using the Modiﬁcation of Diet in Renal Disease formula. BMI indicates body mass
index; BP-SES, biodegradable-polymer sirolimus-eluting stent; DP-EES, durable-polymer everolimus-eluting stent.
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